Swanson, C. http://orcid.org/0000-0003-1554-0862
Shea, S. A.
Wolfe, P.
Markwardt, S.
Cain, S. W.
Munch, M.
Czeisler, C. A.
Orwoll, E. S.
Buxton, O. M.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (T32 DK007674, T32 DK007446)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23 AR070275)
Medical Research Foundation of Oregon (MRF515)
National Center for Advancing Translational Sciences (UL1TR000128)
National Institute on Aging (P01 AG009975)
Article History
Received: 2 May 2017
Accepted: 12 July 2017
First Online: 26 July 2017
Compliance with ethical standards
:
: In the interest of full disclosure, we report the following; however, we do not believe any of these pertain to the current work.C.M.S. received support from NIH grant T32 DK007674, NIH grant T32 DK007446, K23 AR070275, and the Medical Research Foundation of Oregon Early Clinical Investigator Grant MRF515.S.A.S. received support from NASA grant NNX1OAR1OG, CDC grant U19 OH010154, and NIH grant R01 HL125893.P.W., S.W.C., and M.M. have no disclosures.S.M. received support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1TR000128 from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH).C.A.C. is consultant to ExternalRef removed, Inc., A2Z Development Center, Bose, Boston Celtics, Boston Red Sox, Cleveland Browns, Columbia River Bar Pilots, Institute of Digital Media and Child Development, Jazz Pharma, Merck, NBA Coaches Association, Purdue Pharma, Quest Diagnostics, Samsung, Teva, and Vanda Pharma. C.A.C. holds equity in Vanda Pharma; receives research/education support from Cephalon, Mary Ann & Stanley Snider via Combined Jewish Philanthropies, NFL Charities, Jazz Pharma, Optum, ResMed, San Francisco Bar Pilots, Schneider, Simmons, Sysco, Philips, and Vanda; is an expert witness in legal cases, including those involving Bombardier, Continental Airlines, Fedex, Greyhound, Purdue Pharma, and UPS; serves as the incumbent of a professorship endowed by Cephalon; and receives royalties from McGraw Hill, Houghton Miflin Harcourt, and Philips Respironics for the Actiwatch-2 and Actiwatch Spectrum devices. C.A.C.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies.O.M.B. previously served as consultant to Takeda Pharmaceuticals North America (speaker’s bureau), Dinsmore LLC (expert witness testimony), Matsutani America (scientific advisory board), and Chevron (speaking fees). Outside of the submitted work, investigator-initiated research grant support from Sepracor (now Sunovion) and Cephalon (now Teva). This work was supported by grants from the National Institute on Aging (NIA) (P01 AG009975) and was conducted in the Brigham and Women’s Hospital General Clinical Research Center supported by the National Center for Research Resources (NCRR) (M01 RR02635), the CCI of the Harvard Clinical and Translational Science Center (1 UL1 RR025758-01), and with support from the Joslin Diabetes and Endocrinology Research Center Service (5P30 DK 36836) Specialized Assay Core. O.M.B. was supported in part by the NHLBI (R01HL107240).E.S.O. consults for and has received research support from Amgen, Lilly, and Merck.E.S.O. for The Osteoporotic Fractures in Men (MrOS) Study, and the National Institutes of Health via the following institutes: the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research, under the following grant numbers: U01AG027810, U01 AG042124, U01 AG042139, U01 AG042140,U01 AG042143, U01 AG042145, U01 AG042168, U01AR066160, and UL1 TR000128.